FDA Class II Recall Issued for IMRIS ORT200 Operating Room Tables
The FDA has announced a Class II recall of certain IMRIS ORT200 operating room tables due to a mechanical failure risk that could cause unintended movement during procedures.
Every recalls & safety alerts report published for Minnesota, newest first.
The FDA has announced a Class II recall of certain IMRIS ORT200 operating room tables due to a mechanical failure risk that could cause unintended movement during procedures.
An open Class II recall covers 1,424 arterial cannula units distributed worldwide due to potential pinhole leaks.
The agency has closed the recall of certain Medtronic arterial cannulas, considering it carried out.
The ongoing Class II recall covers 3,621 units of arterial return cannulas due to potential pinhole leaks.
An FDA enforcement report lists the Class II recall, initiated June 11, 2026, as ongoing, citing hemostatic valve damage linked to dilator insertion during device preparation.
An FDA enforcement report lists 5,471 units of the 0.5 fl oz product recalled nationwide as subpotent, with the action initiated June 25, 2026.
An FDA enforcement report lists a Class II action covering six pulsed field ablation generators distributed in five European countries.
An FDA enforcement report lists the Class II action, initiated June 11, 2026, as ongoing after devices shipped with instructions omitting FARAPOINT PFA catheter information.
An ongoing nationwide recall of a single lot "Lot:1505141", "exp 2027-04." cites a sub-potent drug with low pH and a significantly reduced assay, according to the agency's enforcement record.
The agency's enforcement report cites a sub-potent drug with low pH and a significantly reduced assay; the recall is listed as ongoing.
An FDA enforcement report says instructions supplied with the device omitted FARAPOINT PFA catheter information; the Class II action is listed as ongoing.
An FDA enforcement report lists 11,977 units of a carbamide peroxide 6.5% kit recalled nationwide as subpotent, with the action still ongoing.
An FDA enforcement report classifies the ongoing Class II action, which covers units distributed in nine European countries, as a labeling discrepancy.
An FDA enforcement report lists 15,843 units of the 6.5% ear drops recalled by Bell Pharmaceuticals, Inc for reduced potency; the action is ongoing.